Additional Study Information: The purpose of this study is to compare the effects, good or bad, of the cancer immunotherapy (CIT) combinations on you and your liver cancer, to find out which is better when given prior to surgery to remove your cancer. The study drugs are Atezolizumab, Bevacizumab, Tiragolumab, and RO7247669. The CIT combinations are experimental drug treatments, which means health authorities have not approved them for the treatment of liver cancer in the neoadjuvant for treating cancer before surgery.